Houston biopharma company CoRegen said it has received US Food and Drug Administration clearance to begin a Phase I/II trial of CRG-150, an adoptive cell therapy targeting steroid receptor coactivator ...
The firm said it will use the funds to advance its KRAS-targeted cancer vaccine ELI-002 7P in KRAS-driven pancreatic cancer.
The gene therapy for multiple sulfatase deficiency was one of the preclinical programs the Bespoke Gene Therapy Consortium selected for its pilot.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results